Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3548-3556

  Andrés Guerrero, Vanessa ^a   Vicario de la Torre, Marta ^a   Molina Martínez, Irene T ^a   Benítez del Castillo, José Manuel ^b   García Feijoo, Julián ^b   Herrero Vanrell, Rocío ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BIOPOLYMER; CARBOXYMETHYLCELLULOSE; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; TIMOLOL MALEATE; DRUG; DRUG DERIVATIVE; EYE DROPS; METHYLCELLULOSE; PRESERVATIVE; TIMOLOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG TOLERANCE; DRY EYE; EYE TOXICITY; GLAUCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; NORMAL HUMAN; OCULOPLETHYSMOGRAPHY; OSMOLARITY; PH; PRIORITY JOURNAL; RABBIT; SPECTROPHOTOMETRY; ANIMAL; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; CONJUNCTIVA; DRUG EFFECT; FLOW KINETICS; PATHOLOGY;

ANIMALS; CARBOXYMETHYLCELLULOSE SODIUM; CELL SURVIVAL; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CONJUNCTIVA; EPITHELIUM, CORNEAL; HUMANS; HYALURONIC ACID; HYDROGEN-ION CONCENTRATION; INTRAOCULAR PRESSURE; MALE; METHYLCELLULOSE; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PHARMACEUTICAL PREPARATIONS; PRESERVATIVES, PHARMACEUTICAL; RABBITS; RHEOLOGY; TIMOLOL; TONOMETRY, OCULAR;

EID: 80051716146     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6338     Document Type: Article

References (70)

1. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther. 2000;22:167-208.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
3. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-1135.
4. Lang LC. Ocular drug delivery: conventional ocular formulations, Adv Drug Deliv Rev. 1995;16:39-43.
5. Curtis C, Lo E, Ooi L, Bennett L, Long J. Factors affecting compliance with eye drop therapy for glaucoma in a multicultural outpatient setting. Contemp Nurse. 2009;31:121-128.
6. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43:454-461.
7. Gray TA, Orton LC, Henson D, Harper R, Waterman H. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2009;CD006132.
8. Kalavala M, Statham BN. Allergic contact dermatitis from timolol and dorzolamide eye drops. Contact Dermatitis. 2006;54:345-350.
9. Quiralte J, Florido F, de San Pedro BS. Allergic contact dermatitis from carteolol and timolol in eyedrops. Contact Dermatitis. 2000; 42:245-250.
10. Camras CB, Toris CB, Tamesis RR. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging. 1999;15:377-388.
11. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725-735 e721.
12. Baffa Ldo P, Ricardo JR, Dias AC, et al. Tear film and ocular surface alterations in chronic users of antiglaucoma medications. Arq Bras Oftalmol. 2008;71:18-21.
13. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128.
14. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572-579.
15. Ali FS, Akpek EK. Glaucoma and dry eye. Ophthalmology. 2008; 115:109-115.
16. Detry-Morel M. Side effects of glaucoma medications (review) Bull Soc Belge Ophtalmol. 2006;299:27-40.
17. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservativefree glaucoma medications. Eur J Ophthalmol. 2007;17:341-349.
18. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39-42.
19. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339-343.
20. Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008;33:303-312.
21. Bai T, Huang JF, Wang W. Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface. Cutan Ocul Toxicol. 2010;29:247-253.
22. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134-139.
23. Becquet F, Goldschild M, Moldovan MS, Ettaiche M, Gastaud P, Baudouin C. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17:419-425.
24. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25:15-30.
25. Diebold Y, Herreras JM, Callejo S, Argueso P, Calonge M. Carbomer-versus cellulose-based artificial-tear formulations: morphologic and toxicologic effects on a corneal cell line. Cornea. 1998; 17:433-440.
26. Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-334.
27. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004;32:180-184.
28. Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42:642-652.
29. Chang SC, Chien DS, Bundgaard H, Lee VH. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp Eye Res. 1988;46:59-69.
30. Kyyronen K, Urtti A. Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine. Invest Ophthalmol Vis Sci. 1990;31:1827-1833.
31. Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005;80:629-632.
32. Hosseini A, Lattanzio FA, Williams PB, Tibbs D, Samudre SS, Allen RC. Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp Eye Res. 2006;82:753-759.
33. Arnold JJ, Choksi Y, Chen X, et al. Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits. J Ocul Pharmacol Ther. 2009;25:179-186.
34. Andres-Guerrero V, Alarma-Estrany P, Molina-Martinez IT, Peral A, Herrero-Vanrell R, Pintor J. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Exp Eye Res. 2009;88:504-511.
35. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007;24:302-309.
36. Franks W. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22:1643-1649.
37. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18:293-300.
38. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther. 2009;25:239-248.
39. von der Ohe N, Stark M, Mayer H, Brewitt H. How can the bioavailability of timolol be enhanced?-a pharmacokinetic pilot study of novel hydrogels. Graefes Arch Clin Exp Ophthalmol. 1996;234:452-456.
40. Burgalassi S, Chetoni P, Panichi L, Boldrini E, Saettone MF. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther. 2000;16: 497-509.
41. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the ocular bioavailability of timolol by sorbic acid. Int J Pharm. 2004; 272:91-98.
42. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm. 2007;338:21-26.
43. Patton TF, Robinson JR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci. 1975;64:1312-1316.
44. Saettone MF, Giannaccini B, Teneggi A, Savigni P, Tellini N. Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man. J Pharm Pharmacol. 1982;34:464-466.
45. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595-1639.
46. Johnston TP, Dias CS, Mitra AK. Ophthalmic Drug Delivery System. 2nd ed. New York: Marcel Dekker; 2003;409-435.
47. Robinson JR. Mechanism (s) of corneal drug transport and mucoadhesive delivery systems. Ocul Drug Deliv. 1989;5:839-850.
48. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001;215:143-155.
49. Mundada AS, Avari JG. In situ gelling polymers in ocular drug delivery systems: a review. Crit Rev Ther Drug Carrier Syst. 2009;26:85-118.
50. Benedetto DA, Shah DO, Kaufman HE. The instilled fluid dynamics and surface chemistry of polymers in the preocular tear film. Invest Ophthalmol. 1975;14:887-902.
51. Herrero-Vanrell R, Fernandez-Carballido A, Frutos G, Cadorniga R. Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J Ocul Pharmacol Ther. 2000;16:419-428.
52. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86:181-184.
53. Bartlett JD. Ophthalmic Drug Facts: Facts and Comparisons. 21st ed. Hagerstown, MD: Lippincott Williams & Wilkins; 2009:109-120.
54. Erk N. Simultaneous determination of dorzolamide HCL and timolol maleate in eye drops by two different spectroscopic methods. J Pharm Biomed Anal. 2002;28:391-397.
55. Morgan PB, Soh MP, Efron N. Corneal surface temperature decreases with age. Cont Lens Anterior Eye. 1999;22:11-13.
56. Acosta MC, Berenguer-Ruiz L, Garcia-Galvez A, Perea-Tortosa D, Gallar J, Belmonte C. Changes in mechanical, chemical, and thermal sensitivity of the cornea after topical application of nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci. 2005;46: 282-286.
57. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48:4827-4833.
58. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem. 1997;69:581-593.
59. Gipson IK, Spurr-Michaud S, Argueso P, Tisdale A, Ng TF, Russo CL. Mucin gene expression in immortalized human corneal-limbal and conjunctival epithelial cell lines. Invest Ophthalmol Vis Sci. 2003;44:2496-2506.
60. Pouliquen Y, Patey A, Foster CS, Goichot L, Savoldelli M. Druginduced cicatricial pemphigoid affecting the conjunctiva: light and electron microscopic features. Ophthalmology. 1986;93:775-783.
61. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12: 486-490.
62. Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology. 2006;113:1333-1339.
63. Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Exp Ophthalmol. 2008;36:553-559.
64. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423.
65. Burstein NL. Clinical Ocular Pharmacology. Boston: Butterworth-Heinemann; 1997:21-45.
66. Carney LG, Hill RM. Human tear pH: diurnal variations. Arch Ophthalmol. 1976;94:821-824.
67. Chrai SS, Robinson JR. Ocular evaluation of methylcellulose vehicle in albino rabbits. J Pharm Sci. 1974;63:1218-1223.
68. Calonge M. The treatment of dry eye. Surv Ophthalmol. 2001; 45(suppl 2):S227-S239.
69. Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci. 2008;85:750-757.
70. Kyyronen K, Urtti A. Effects of epinephrine pretreatment and solution pH on ocular and systemic absorption of ocularly applied timolol in rabbits. J Pharm Sci. 1990;79:688-691.